367
Participants
Start Date
June 8, 2021
Primary Completion Date
August 22, 2025
Study Completion Date
November 18, 2026
Medi-546
Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.
Placebo
Solution for injection in aPFS
Research Site, Budapest
Research Site, Budapest
Research Site, Quezon City
Research Site, Sofia
Research Site, Sofia
Research Site, Sofia
Research Site, San Isidro
Research Site, Sofia
Research Site, Sofia
Research Site, La Plata
Research Site, San Miguel de Tucumán
Research Site, Plovdiv
Research Site, San Juan
Research Site, Sevlievo
Research Site, Mendoza
Research Site, Gyula
Research Site, Pleven
Research Site, Kardzhali
Research Site, Székesfehérvár
Research Site, Barcelona
Research Site, Barcelona
Research Site, Veszprém
Research Site, New York
Research Site, Berlin
Research Site, Rachathewi
Research Site, Manhasset
Research Site, Brooklyn
Research Site, Potsdam
Research Site, Pittsburgh
Research Site, Santiago de Compostela
Research Site, Reading
Research Site, Vinnytsia
Research Site, Vinnytsia
Research Site, Mexicali
Research Site, Charlotte
Research Site, Charlotte
Research Site, Madrid
Research Site, Chihuahua City
Research Site, Miami
Research Site, Brandon
Research Site, Tampa
Research Site, Tampa
Research Site, Clearwater
Research Site, Clearwater
Research Site, Birmingham
Research Site, Memphis
Research Site, Seville
Research Site, Durango
Research Site, Guadalajara
Research Site, Guadalajara
Research Site, Guadalajara
Research Site, Valencia
Research Site, Flint
Research Site, Lansing
Research Site, Muang
Research Site, Cologne
Research Site, Odesa
Research Site, Zaporizhzhia
Research Site, Tübingen
Research Site, Oklahoma City
Research Site, Grapevine
Research Site, Culiacán
Research Site, Aurora
Research Site, Idaho Falls
Research Site, Phoenix
Research Site, Paradise Valley
Research Site, Las Cruces
Research Site, Los Angeles
Research Site, Upland
Research Site, La Mesa
Research Site, El Cajon
Research Site, Hemet
Research Site, Menifee
Research Site, Fullerton
Research Site, Mérida
Research Site, Mérida
Research Site, Bogotá
Research Site, Montería
Research Site, Chía
Research Site, Bucaramanga
Research Site, Valdivia
Research Site, Osorno
Research Site, Santiago
Research Site, Santiago
Research Site, Santiago
Research Site, Santiago
Research Site, Santiago
Research Site, Santiago
Research Site, Newark
Research Site, Ciudad de Buenos Aires
Research Site, Pergamino
Research Site, Quilmes
Research Site, Rosario
Research Site, Salta
Research Site, San Miguel de Tucumán
Research Site, San Miguel de Tucumán
Research Site, Barranquilla
Research Site, Barranquilla
Research Site, Leipzig
Research Site, Chiba
Research Site, Chūōku
Research Site, Hamamatsu
Research Site, Hiroshima
Research Site, Itabashi-ku
Research Site, Kita-gun
Research Site, Kitakyushu-shi
Research Site, Meguro-ku
Research Site, Meguro-ku
Research Site, Nagasaki
Research Site, Nagoya
Research Site, Nagoya
Research Site, Okayama
Research Site, Sagamihara-shi
Research Site, Sasebo-shi
Research Site, Sendai
Research Site, Shinjuku-ku
Research Site, México
Research Site, México
Research Site, México
Research Site, Katowice
Research Site, Kościan
Research Site, Krakow
Research Site, Krakow
Research Site, Krakow
Research Site, Lodz
Research Site, Lublin
Research Site, Nowa Sól
Research Site, Ustroń
Research Site, Warsaw
Research Site, Warsaw
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Wroclaw
Research Site, Barcelona
Research Site, Kyiv
Research Site, Kyiv
Research Site, Kyiv
Research Site, Doncaster
Research Site, Leeds
Research Site, London
Lead Sponsor
Iqvia Pty Ltd
INDUSTRY
AstraZeneca
INDUSTRY